- NCIt
- C7480
Loading cancer entity…
Loading cancer entity…
Clinical trials
744 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00039585 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00267696 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2015 |
| clinicaltrials |
| NCT01196559 | Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 44 | The Catholic University of KoreaOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT00388037 | Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT00418093 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2014 | clinicaltrials |
| NCT00126542 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00543049 | Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor | completed | Phase 2 | 73 | AGO Study GroupOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00504257 | Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma | completed | Phase 2 | 45 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00003064 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 1 / Phase 2 | 30 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003560 | Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 2 | 40 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00096239 | CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 18, 2013 | clinicaltrials |
| NCT01079832 | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2013 | clinicaltrials |
| NCT00617773 | Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 31 | Recepta BiopharmaINDUSTRY | 1 | Nov 26, 2013 | clinicaltrials |
| NCT00053833 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 2 | Nov 8, 2013 | clinicaltrials |
| NCT00004064 | Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | unknown | Phase 2 | 102 | AltaRexINDUSTRY | 2 | Nov 6, 2013 | clinicaltrials |
| NCT00005025 | Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | unknown | Phase 2 | — | John Stoddard Cancer Center at Iowa Methodist Medical CenterOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00006942 | Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01100372 | Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | unknown | Phase 2 | 154 | Medical University InnsbruckOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00002538 | Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Aug 20, 2013 | clinicaltrials |
| NCT00075712 | Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 / Phase 3 | 150 | Royal College of Obstetricians and GynecologistsOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00305838 | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | unknown | Phase 2 | 200 | Mount Vernon Cancer Centre at Mount Vernon HospitalOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | unknown | Phase 2 / Phase 3 | 241 | Ludwig-Maximilians - University of MunichOTHER | 3 | Aug 7, 2013 | clinicaltrials |
| NCT00014690 | ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | — | AstraZenecaINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00748527 | Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 2 | 134 | Cancer Research UKOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00022347 | TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00138242 | Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 2 | 30 | Floyd & Delores Jones Cancer Institute at Virginia Mason Medical CenterOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00004012 | Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00003345 | Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 21, 2013 | clinicaltrials |
| NCT00019461 | Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00019552 | Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00049556 | Gefitinib in Treating Patients With Cervical Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00012090 | Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00369954 | Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin | withdrawn | Phase 2 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Jun 10, 2013 | clinicaltrials |
| NCT00017017 | CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00003944 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Apr 17, 2013 | clinicaltrials |
| NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | completed | Phase 2 | 68 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 4, 2013 | clinicaltrials |
| NCT01661868 | Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 21, 2012 | clinicaltrials |
| NCT00501644 | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00032162 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | completed | Phase 1 / Phase 2 | 63 | AGO Study GroupOTHER | 1 | May 31, 2012 | clinicaltrials |
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00004060 | Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | — | Daiichi SankyoINDUSTRY | 1 | May 16, 2012 | clinicaltrials |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2012 | clinicaltrials |
| NCT01570582 | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | unknown | Phase 2 | 314 | Korean Gynecologic Oncology GroupOTHER | 1 | Apr 4, 2012 | clinicaltrials |
| NCT00466986 | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 40 | Southeastern Gynecologic OncologyOTHER | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00003160 | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | unknown | Phase 2 | 100 | TheradexINDUSTRY | 1 | Apr 20, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Apr 30, 2015source: clinicaltrials